Trial Profile
Paclitaxel + Bevacizumab versus doxorubicina liposomiale non pegilata (Myocet), cyclophosfamide e Bevacizumab as the first line treatment in HER-2 negative metastatic breast cancer. Multicenter randomized Study of phase II
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 01 Jul 2014
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Cyclophosphamide (Primary) ; Doxorubicin liposomal (Primary) ; Paclitaxel
- Indications Breast cancer
- Focus Therapeutic Use
- 01 Jul 2014 New trial record